Moomoo AI 已提取核心信息
Ardelyx, Inc., a biopharmaceutical company, announced its financial results for the year ended December 31, 2023, on February 22, 2024. The company reported strong commercial performance with $80.1 million in net product sales revenue from IBSRELA and $2.5 million from XPHOZAH, launched in November 2023. Ardelyx ended the year with $184.3 million in cash and investments. The company expects 2024 net product sales revenue for IBSRELA to be between $140.0 to $150.0 million. Ardelyx also highlighted the approval of tenapanor for hyperphosphatemia in Japan and the initiation of a long-term observational study for XPHOZAH. The company's total revenues for 2023 were $124.5 million, a significant increase from $52.2 million in 2022. Research and development expenses remained stable at $35.5 million, while selling, general and administrative expenses increased to $134.4 million due to commercialization efforts. The net loss for the year was $66.1 million, or $(0.30) per share. Ardelyx will host a conference call to discuss these results and updates.
Ardelyx, Inc., a biopharmaceutical company, announced its financial results for the year ended December 31, 2023, on February 22, 2024. The company reported strong commercial performance with $80.1 million in net product sales revenue from IBSRELA and $2.5 million from XPHOZAH, launched in November 2023. Ardelyx ended the year with $184.3 million in cash and investments. The company expects 2024 net product sales revenue for IBSRELA to be between $140.0 to $150.0 million. Ardelyx also highlighted the approval of tenapanor for hyperphosphatemia in Japan and the initiation of a long-term observational study for XPHOZAH. The company's total revenues for 2023 were $124.5 million, a significant increase from $52.2 million in 2022. Research and development expenses remained stable at $35.5 million, while selling, general and administrative expenses increased to $134.4 million due to commercialization efforts. The net loss for the year was $66.1 million, or $(0.30) per share. Ardelyx will host a conference call to discuss these results and updates.
生物制药公司Ardelyx, Inc. 于2024年2月22日公布了截至2023年12月31日的年度财务业绩。该公司公布了强劲的商业业绩，IBSRELA的产品净销售收入为8,010万美元，XPHOZAH于2023年11月推出，净产品销售收入为250万美元。Ardelyx在年底拥有1.843亿美元的现金和投资。该公司预计，IBSRELA2024年的净产品销售收入将在1.4亿美元至1.5亿美元之间。Ardelyx还强调了日本批准tenapanor治疗高磷血症以及XPHOZAH的长期观察性研究的启动。该公司2023年的总收入为1.245亿美元，较2022年的5,220万美元大幅增加。研发费用稳定在3550万美元，而由于商业化努力，销售、一般和管理费用增至1.344亿美元。该年度的净亏损为6,610万美元，合每股亏损0.30美元。Ardelyx 将主持电话会议，讨论这些结果和更新。
生物制药公司Ardelyx, Inc. 于2024年2月22日公布了截至2023年12月31日的年度财务业绩。该公司公布了强劲的商业业绩，IBSRELA的产品净销售收入为8,010万美元，XPHOZAH于2023年11月推出，净产品销售收入为250万美元。Ardelyx在年底拥有1.843亿美元的现金和投资。该公司预计，IBSRELA2024年的净产品销售收入将在1.4亿美元至1.5亿美元之间。Ardelyx还强调了日本批准tenapanor治疗高磷血症以及XPHOZAH的长期观察性研究的启动。该公司2023年的总收入为1.245亿美元，较2022年的5,220万美元大幅增加。研发费用稳定在3550万美元，而由于商业化努力，销售、一般和管理费用增至1.344亿美元。该年度的净亏损为6,610万美元，合每股亏损0.30美元。Ardelyx 将主持电话会议，讨论这些结果和更新。
有用
没用